New possibilities of combined antiandrogen therapy in patients with metastatic hormone-sensitive prostate cancer
Currently, enzalutamide is the standard of pharmaceutical therapy of metastatic and non-metastatic castration-resistant prostate cancer. However, until recently there was no data on effectiveness and safety of enzalutamide in metastatic hormone-sensitive prostate cancer. Results of 2 large randomize...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2019-10-01
|
| Series: | Onkourologiâ |
| Subjects: | |
| Online Access: | https://oncourology.abvpress.ru/oncur/article/view/987 |